scholarly journals Serum Cytokines Profile in Treated Celiac Disease Compared with Non-celiac Gluten Sensitivity and Control: a Marker for Differentiation

2018 ◽  
Vol 27 (3) ◽  
pp. 241-247 ◽  
Author(s):  
Fatemeh Heydari ◽  
Mohammad Rostami-Nejad ◽  
Ali Moheb-Alian ◽  
Mostafa Haji Mollahoseini ◽  
Kamran Rostami ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Inflammatory Cytokines ◽  
Clinical Symptoms ◽  
Elevated Serum ◽  
Serum Levels ◽  
Mucosal Damage ◽  
Gluten Sensitivity ◽  
Ifn Γ ◽  
The Mean ◽  
And Control

Background & Aims: There is increasing evidence regarding elevated serum levels of inflammatory cytokines in patients with celiac disease (CD), but little is known about their levels in patients with non-celiac gluten sensitivity (NCGS). The aim of this study was to evaluate the serum levels of inflammatory cytokines in Iranian patients with CD and NCGS and to compare them with those of healthy individuals. Methods: A total of 110 treated CD, 15 with NCGS, and 46 healthy subjects were enrolled during 2016. Serum levels of IL-1, IL-6, IL-8, IL-15 and IFN-γ were measured using ELISA, and compared between groups. The correlation of the severity of mucosal damage and clinical symptoms with serum levels of cytokines was also assessed. Results: The mean serum levels of IFN-γ (p = 0.04) and IL-6 (p = 0.007) were significantly different between the patients in the CD and control groups, and IL-8 was significantly higher in the CD group compared with patients in the NCGS group (p = 0.04). Statistically significant correlations were observed between the serum levels of IFN-γ and abortion (p = 0.01), IL-1 and weight loss (p = 0.043) and infertility (p = 0.0001) in CD patients, and between IFN-γ and abortion (p = 0.01) and infertility (p = 0.01) in the NCGS patients. Moreover, no significant relationship was observed between the severity of mucosal damage and the serum level of the studied cytokines. Conclusions: Inflammatory cytokines are implicated in the pathogenesis of CD, and their serum levels might help to identify a diagnostic marker to differentiate CD from NCGS. However, further studies with a larger sample size are recommended.

scholarly journals Non-Celiac Gluten Sensitivity: A Challenging Diagnosis in Children with Abdominal Pain

2018 ◽  
Vol 73 (Suppl. 4) ◽  
pp. 39-46 ◽  
Author(s):  
Frank M. Ruemmele
Keyword(s):  
Abdominal Pain ◽  
Celiac Disease ◽  
Clinical Symptoms ◽  
Gluten Sensitivity ◽  
Gluten Free ◽  
Clear Cut ◽  
Clinical Presentations ◽  
New Findings ◽  
Three Phase ◽  
Gi Symptoms

Several disorders related to the ingestion of gluten are well recognized despite overlapping clinical presentations: celiac disease, an autoimmune enteropathy triggered by gluten ingestions in susceptible individuals, allergy to wheat, and more recently non-celiac gluten sensitivity (NCGS). While celiac disease and wheat allergy are well-known disorders with a clear-cut diagnosis based on clinical tests and biological parameters, NCGS is a more difficult diagnosis, especially in children with functional gastrointestinal (GI) complaints. NCGS is considered a syndrome of intestinal but also extraintestinal symptoms occurring within hours, but sometimes even after several days of gluten ingestion. In children, the leading symptoms of NCGS are abdominal pain and diarrhea, while extraintestinal symptoms are rare, in contrast to adult patients. No precise diagnostic test nor specific biomarkers exist, except a rather cumbersome three-phase gluten-exposure, gluten-free diet, followed by a blinded placebo-controlled gluten challenge with crossover to provoke symptoms elicited by gluten in a reproducible manner that disappear on gluten-free alimentation. Recent data indicate that the peptide part of wheat proteins is not necessarily the sole trigger of clinical symptoms. Mono- or oligosaccharides, such as fructan and other constituents of wheat, were able to provoke GI symptoms in clinical trials. These new findings indicate that the term gluten sensitivity is probably too restrictive. The incidence of NCGS was reported in the range of 1–10% in the general population and to increase steadily; however, most data are based on patients’ self-reported gluten intolerance or avoidance without a medically confirmed diagnosis. Treatment consists of gluten avoidance for at least several weeks or months. Patients with NCGS require regular reassessment for gluten tolerance allowing with time the reintroduction of increasing amounts of gluten.

scholarly journals D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients.

1998 ◽  
Vol 9 (1) ◽  
pp. 90-96
Author(s):  
C Bommer ◽  
E Werle ◽  
I Walter-Sack ◽  
C Keller ◽  
F Gehlen ◽  
...  
Keyword(s):  
Serum Concentration ◽  
Ldl Cholesterol ◽  
Clinical Symptoms ◽  
Hormone Secretion ◽  
Elevated Serum ◽  
Serum Levels ◽  
Controlled Study ◽  
Dialysis Patients ◽  
Lipoprotein A ◽  
Thyroxine Therapy

Uremia raises lipoprotein(a) (Lp(a)) serum concentration and the risk of arteriosclerosis in dialysis patients. The treatment of high Lp(a) levels is not satisfactory today. The decrease of Lp(a) in hypothyroid patients on L-T4 therapy raised the question of whether dextro-thyroxine (D-thyroxine) reduces not only serum cholesterol, but also Lp(a) serum concentration. In a single-blind placebo-controlled study, the influence of D-thyroxine therapy on Lp(a) serum concentration was evaluated in 30 hemodialysis patients with elevated Lp(a) serum levels. Lp(a) was quantified in parallel by two methods, i.e., rocket immunoelectrophoresis and nephelometry, and apo(a) isoforms were determined by a sensitive immunoblotting technique. Regardless of the apo(a) isoforms, 6 mg/d D-thyroxine reduced elevated Lp(a) levels significantly by 27 +/- 13% in 20 dialysis patients (P < 0.001) compared with 10 control subjects (-9.9 +/- 8.4%). In parallel, D-thyroxine therapy significantly lowered total cholesterol (P < 0.001), LDL cholesterol (P < 0.001), and LDL cholesterol/HDL cholesterol ratio (P < 0.01); raised T4 and T3 serum levels; and suppressed thyroid-stimulating hormone secretion without causing clinical symptoms of hyperthyroidism in any of the patients. D-Thyroxine reduces elevated serum Lp(a) concentration in dialysis patients. The effect in nondialysis patients can be expected but remains to be proven.

scholarly journals Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome

2020 ◽  
Vol 7 ◽  
Author(s):  
Hana A. Itani ◽  
Miran A. Jaffa ◽  
Joseph Elias ◽  
Mohammad Sabra ◽  
Patrick Zakka ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Inflammatory Cytokines ◽  
Statistical Significance ◽  
Serum Levels ◽  
Tissue Growth ◽  
Cardiometabolic Syndrome ◽  
Proteomic Study ◽  
Obesity Hypertension ◽  
High Level ◽  
And Control

Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin resistance/glucose intolerance are also associated with inflammation and increased level of cytokines and adipokines. We hypothesized that the inflammatory immune response is exacerbated in patients with both AF and CMS compared to either AF or CMS alone. We investigated inflammatory cytokines and fibrotic markers as well as cytokine genetic profiles in patients with lone AF and CMS. CMS, lone AF patients, patients with both lone AF and CMS, and control patients were recruited. Genetic polymorphisms in inflammatory and fibrotic markers were assessed. Serum levels of connective tissue growth factor (CTGF) were tested along with other inflammatory markers including platelet-to-lymphocyte ratio (PLR), monocyte-to-HDL ratio (MHR) in three groups of AF+CMS, AF, and CMS patients. There was a trend in the CTGF levels for statistical significance between the AF and AF+CMS group (P = 0.084). Genotyping showed high percentages of patients in all groups with high secretor genotypes of Interleukin-6 (IL-6) (P = 0.037). Genotyping of IFN-γ and IL-10 at high level showed an increase in expression in the AF + CMS group compared to AF and CMS alone suggesting an imbalance between the inflammatory and anti-inflammatory cytokines which is exacerbated by AF. Serum cytokine inflammatory cytokine levels showed that IL-4, IL-5, IL-10, IL-17F, and IL-22 were significant between the AF, AF+CMS, and CMS patients. Combination of both CMS and AF may be associated with a higher degree of inflammation than what is seen in either CMS or AF alone. Thus, the identification of a biomarker capable of identifying metabolic syndrome associated with disease will help in identification of a therapeutic target in treating this devastating disease.

Use of Erythropoietin (EPO) in Children with Malignancies.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5533-5533
Author(s):  
Gabor T. Kovacs ◽  
Judit Muller ◽  
Monika Csoka ◽  
Eszter Vonnak ◽  
Hajna Erlaky ◽  
...  
Keyword(s):  
Pediatric Population ◽  
Lymphoblastic Leukemia ◽  
Elevated Serum ◽  
Serum Levels ◽  
Control Group ◽  
Recombinant Erythropoietin ◽  
Malignant Diseases ◽  
Human Erythropoietin ◽  
Unsuccessful Treatment ◽  
The Mean

Abstract Recombinant erythropoietin is widely used for the treatment of anemia in malignant diseases in adults. There are only limited data of its use in pediatric population. In this study we analysed the effectiveness and tolerability of recombinant human erythropoietin (NeoRecormon) in children with malignant diseases. 80 children with malignant diseases were analysed. 40 patients (15 girls, 25 boys) received EPO in a mean dosage of 144.5±14.1 IU/kg three times a week. The mean age of the EPO-treated patients was 8.8 (2.5–16) years. 26 children had acute lymphoblastic leukemia and 14 patients had solid tumor. Match-paired, retrospective control patients (n=40) with similar diagnosis were used for the data analysis as control group (C). The mean duration of EPO treatment was 5.8 months (3–8 mo). In 6 patients the therapy was ceased due to elevated serum hemoglobin (Hb) (>130 g/L), in 6 patients the dose was increased up to 200 IU/kg three times a week, and 5 patients discontinued the therapy (2 died, 3 unsuccessful treatment). The mean amount of erythrocyte transfusion in the first 3 months of chemotherapy (CT) was 4.1±3.1 U/patient in the EPO group, and 8.0±4.2 in C, and during 6 months of CT 4.5±3.4 with EPO, and 11.6±7.1 in C (p<0.05). Soluble transferrine receptor (STFR) levels in serum increased in the EPO group after 2 weeks of therapy from 3.2±2.0 up to 4.8±2.9 (p<0.05). In general in 26/40 patients a significant elevation of the Hb levels and decrease of the need of erythrocyte transfusions could be detected. In 22 patients the STFR levels increased more than 50 % after 2 weeks of therapy. In this subgroup 18/22 children responded to EPO therapy. All patients tolerated the therapy well, no severe side effects were detected. In summary, EPO treatment is effective in about 2/3 of pediatric oncology patients. The therapy is well-tolerated. Increase in the STFR serum levels might be a useful marker for the effectiveness of EPO in children.

Relative value of serum cytokines and clinical factors in predicting weight loss in advanced pancreatic cancer (PC).

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 208-208
Author(s):  
D. R. Fogelman ◽  
X. S. Wang ◽  
M. Hassan ◽  
D. Li ◽  
M. M. Javle ◽  
...  
Keyword(s):  
Weight Loss ◽  
High Risk ◽  
Clinical Symptoms ◽  
Advanced Pancreatic Cancer ◽  
Serum Levels ◽  
Baseline Serum ◽  
Mean Values ◽  
Cytokine Analysis ◽  
Predict Weight Loss ◽  
The Mean

208 Background: The identification of PC patients at high risk for cachexia may allow for early intervention to prevent this outcome. Symptoms such as pain, nausea, and anorexia might predict weight loss. Likewise, inflammatory cytokines are also associated with cachexia. We evaluated the ability of each to predict weight loss in patients beginning treatment for PC. Methods: We evaluated 44 newly diagnosed advanced or metastatic PC patients for baseline symptomatology via the M. D. Anderson Symptom Inventory (MDASI). This survey assesses symptom severity, such as nausea, vomiting, fatigue, pain, diarrhea, and constipation, on a 1-10 scale. Baseline serum levels of IL-1a, IL-1b, IGF-1, CXCL-12, CXCL-16, CRP, IL-6, IL-8, VEGF, CEA, and CA 19-9 were assessed. Logistic regression analysis was performed to determine the odds ratio (OR) and confidence interval (CI) for the association of different parameters with 10% weight loss at 60 days from treatment initiation. Student t-test was used to compare the mean values across different strata. Results: A weight loss of >10% was observed in 15 patients (34%). Only the use of mild (but not strong) opioids was associated with weight loss; estimated OR = 6.2 (C.I. 1.2-31.9, p=.03). No association was observed for the MDASI parameters. Baseline levels of cytokines were available for 23 patients. We observed significant differences in the mean values of CXCL-16 (p=.05) and IL-6 (p=.045) in patients with weight loss as compared to those without weight loss. Moreover, serum level of erythropoietin may be negatively associated with weight loss (p=0.06). Conclusions: Alterations in serum cytokine levels may correlate more strongly with cachexia than clinical symptoms and underscore the importance of cytokine analysis in identifying PC patients at high risk for cachexia. [Table: see text]

scholarly journals Changes in interleukin-27 levels in patients with acute coronary syndrome and their clinical significance

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e5652 ◽  
Author(s):  
Lin Zhang ◽  
Junfeng Zhang ◽  
Shaohong Su ◽  
Suyan Luo
Keyword(s):  
Acute Coronary Syndrome ◽  
Angina Pectoris ◽  
Th17 Cells ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Groups ◽  
Coronary Syndrome ◽  
Significant Difference ◽  
Ifn Γ ◽  
And Control

Background This study evaluated changes in interleukin (IL)-27 levels in patients with acute coronary syndrome (ACS) and their influence on Th1, Th2, and Th17 cells. Methods Serum levels of IL-27, IL-4, IL-17, and interferon (IFN)-γ in healthy subjects as well as patients with ACS, including stable angina pectoris (SA), unstable angina pectoris (UA), and acute myocardial infarction (AMI), were determined using an enzyme-linked immunosorbent assay. The proportions of Th1, Th2, and Th17 cells among peripheral blood mononuclear cells (PBMCs), were measured using flow cytometry, after incubation with phorbol myristate acetate (PMA) for 4 h. The proportions of Th1 and Th17 cells among PBMCs in AMI and UA were detected after stimulation with IL-27 or PMA + IL-27 for 4, 8, and 12 h. Results Serum levels of IL-27 in patients with AMI and UA were significantly lower than those in SA and control groups, while serum levels of IL-17 and IFN-γ in AMI and UA groups were dramatically increased compared to those in SA and healthy control groups. However, there were no statistically significant differences in serum IL-4. The proportions of Th1 and Th17 cells among PBMCs were statistically significantly higher in the AMI and UA groups than those in the SA and control groups, while there was no statistically significant difference in the proportion of Th2 cells among different groups. For patients with AMI and UA, the effect of co-stimulation of PBMCs with PMA and IL-27 was not significantly different from that of PMA single stimulation, while PMA + IL-27 co-stimulation lowered the Th17 cell proportion significantly compared to PMA single stimulation. Discussion Compared to SA patients and healthy controls, patients with ACS (AMI + UA) had lower serum levels of IL-27 and higher proportions of PBMC Th1 and Th17 cells, which could be attributed to the inhibitory effects of IL-27 on the proliferation of Th17 cells. These results indicated that IL-27 could be a novel therapeutic target in ACS patients.

scholarly journals The Assessment of 25-Hydroxy Vitamin D Serum Level in Asthmatic Patients: A Case-Control Study

2017 ◽  
Vol 5 (2) ◽  
pp. 65-69
Author(s):  
Mohammad Rasoul Sharanjani ◽  
Ebrahim Nadi ◽  
Maryam Vasheghani ◽  
Mohammad Jafari ◽  
Jalal Poorolajal
Keyword(s):  
Vitamin D ◽  
Serum Levels ◽  
Control Group ◽  
Control Groups ◽  
Asthmatic Patients ◽  
25 Hydroxy Vitamin D ◽  
The Mean ◽  
25 Oh Vitamin D ◽  
And Control ◽  
Control Study

Background: The prevalence of vitamin D deficiency is increasing due to changes in lifestyle and dietary habits. The aim of this study was to compare the serum levels of 25-hydroxy vitamin D between patients with bronchial asthma and the healthy control group. Patients and Methods: In this case-control study, 45 patients with asthma and 45 healthy subjects were enrolled and the level of serum 25 (OH) vitamin D was measured in both groups. In addition, a welltrained observer assessed airway reversibility, peak flowmetry and spirometry in the participants. The data were statistically analyzed using t test, one-way analysis of variance (ANOVA), and chi-square test with Stata software (version 11). Results: The mean age (±SD) of participants were 49.06 ±16.43 and 46.13 ±16.10 years in case and control groups, respectively (P=.394). The prevalence of vitamin D deficiency was high in both groups (69% in case and 65.5% in control groups). The mean (±SD) serum 25 (OH) vitamin D was 16.24 (±14.98) ng/ml in case group and 17.70 (±16.07) ng/mL in control group (P=.657). We found a positive correlation between the levels of vitamin D and the amount of FEV1 (r=0.2). Conclusions: According to the present study, the mean serum levels of vitamin D differences were not statistically significant between asthmatic patients and control group. However, the results of this study showed a positive relationship between forced expiratory volumes in first second (FEV1) and vitamin D levels

scholarly journals Clinical profile of patients with Seronegative celiac disease

2022 ◽  
Author(s):  
Elham Rahmanipour ◽  
fahimeh attarian ◽  
Mohammad Ghorbani ◽  
Bijan Shahbazkhani ◽  
Vahid Ghavami ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Poor Prognosis ◽  
Clinical Symptoms ◽  
Challenge Test ◽  
Iga Deficiency ◽  
Clinical Profile ◽  
Positive Serology ◽  
Mucosal Atrophy ◽  
Delay In Diagnosis ◽  
The Mean

Abstract Background Celiac disease (1) mostly diagnosed base on positive serology and duodenal mucosal atrophy, but some patients have negative serology and their diagnosis have some limitation, it delay in diagnosis likely accompanied a poor prognosis and high risk of developing complications of CD. The aim of this study was determent clinical profile of patients with Seronegative CD (SNCD). Methods in this retrospective study, 1115+8 patients, that evaluated for CD with mucosal atrophy included between 2010 to2020. All patients with IgA deficiency other IgG based serology for diagnosis of celiac was done and if these antibodies were negative consider as possible SNCD. If they had positive DQ2-DQ8, and clinical symptoms or had positive challenge test after12 months of GFD were considered as SNCD. Results of total 1115 patients 27 (2.4%) had seronegative mucosal atrophy of duodenum and diagnosed as a SNCD (96.2% marsh3), the mean age and BMI in SNCD patients were significantly higher than other CD patients (p<0.05). Conclusion The prevalence of SNCD was 2.4% that likely related to over weighting, so clinicians should be considered high possible of seronegative CD in patients with over weighting and mucosal atrophy of duodenum.

scholarly journals Effect of vitamin D combined with anti-tuberculosis drugs on serum IL-1β, IFN-γ and Th17 cell-associated cytokines for the management of spinal tuberculosis

2021 ◽  
Vol 18 (5) ◽  
pp. 1141-1147
Author(s):  
Fang Yu ◽  
Shen Cailiang
Keyword(s):  
Vitamin D ◽  
Th17 Cell ◽  
Spinal Tuberculosis ◽  
Serum Levels ◽  
Control Group ◽  
Study Group ◽  
Cord Injury ◽  
Ifn Γ ◽  
And Control ◽  
Tgf Β1

Purpose: To investigate the effect of combination of vitamin D and anti-tuberculosis drugs on serum interleukin-1β (IL-1β), interferon-γ (IFN-γ) and helper T 17 (Th17) cell-associated cytokine levels for the treatment of spinal tuberculosis (TB). Methods: Ninety-two spinal TB patients were assigned without bias to two groups (46/group): study group (vitamin D combined with anti-TB drug group) and control group (anti-TB drug group). After treatment for 8 weeks, clinical effectiveness, adverse reactions, visual analog scale (VAS) score, spinal cord injury grade, and serum levels of IL-1β, IFN-γ, Th17, IL-10, TGF-β1, IL-17 and IL-23 were assayed with ELISA, and compared between groups. Results: Study group total effectiveness was significantly higher than that in the control group (95.65 % vs 80.43 %, p < 0.05). Before drug administration, VAS score, degree of spinal cord injury and serum levels of IL-1β, IFN-γ, IL-10, TGF-β1, IL-17 and IL-23 were comparable in the study and control patients (p > 0.05). However, post-treatment, these parameters significantly decreased in both groups (p < 0.05), but were markedly lower in study group patients, relative to controls (p < 0.05). Conclusion: The use of combined treatment of vitamin D and anti-TB drugs is an effective and safe way to alleviate inflammatory response and improve the immunity of spinal TB patients via the regulation of the levels of Th17 cell-related factors.

Sign in / Sign up

Export Citation Format

Share Document